WHERE WE GO TO WORK
Strategy is the starting point.
We stay until it's built, running, and yours.
We go to the places where the work is real, the timeline is fixed, and the answer isn't obvious.
HOW IT COMES TOGETHER
Separate Functions.
One Connected System.
Market Access, Commercial Operations, and Clinical to Commercial don't operate in sequence. They operate in parallel.
A coverage decision shapes the field model. A field execution gap exposes an access problem. A new indication restarts both.
We work across all three because the pressure rarely arrives in a straight line. The vendors, partners, and tools already in the room stay in the room. Our job is to make the system around you perform.
MARKET ACCESS
Payers decide before launch. Most companies plan after it.
We've been in the room with the payers, PBMs, and channel partners who decide whether your therapy gets covered. We know what moves them, what stalls them, and where the leverage actually sits.
Prior auth pull-through strategy
Step therapy navigation
SP network optimization
PSP utilization at point of prescribing
Formulary tier positioning
PBM engagement and sequencing
Coverage-to-commitment strategy
Pricing and rebating
COMMERCIAL OPERATIONS
The field model that got you to launch won't get you through growth.
Building from scratch or rebuilding what broke under scale. We know what breaks first, what gets skipped when time runs short, and which early decisions determine whether month 18 holds or goes sideways.
Field force deployment and redesign
Field force effectiveness (FFE)
CSO strategy, design, and optimization
Performance data / revenue decisions
Converting formulary wins into scripts
IC design tied to the right behaviors
CRM and governance the field uses
Build vs. buy decisions
CLINICAL TO COMMERCIAL
The evidence that wins approval isn't the same evidence that wins coverage.
The evidence that wins regulatory approval is rarely the evidence that wins coverage. We design the evidence base backward from payer needs, so what's built for approval is also built for access. That sequencing starts years before launch.
Indication-specific value proposition
Evidence gap analysis
Label expansion and HCP education
Payer sequencing for new indications
Lifecycle positioning
Payer narrative to win coverage
DEPTH EARNED
The Experience Behind the Work.
Our team has been inside these situations. That's why we know how to navigate them; where it breaks, what to skip, and what to do when the timeline won't move.
LAUNCH READINESS / CATEGORY CREATION
A first-in-class therapy. No category. No playbook. No precedent.
No territory model. No IC framework. No payer template to borrow from. We built the entire commercial infrastructure from scratch and launched it in a market that had never existed - challenging the therapeutic market leaders with an alternative
Neurology / PDT Full Commercial Build, Pre-IPO
MARKET ACCESS / PBM CONTRACTING
Men's health has a payer problem that no one in this industry wants to talk about.
PBMs treat men's health therapies as lifestyle products by default. The clinical evidence rarely gets a fair hearing. We built the economic and clinical argument from the ground up, ran the payer conversations, and secured the formulary placement.
Men's Health PBM Formulary Access and Contracting
M&A INTEGRATION
A landmark acquisition. Legacy processes nobody wanted to let go of. A vendor taking orders instead of leading.
Multi-TA Global Commercial Integration
The integration was stalling. Two operating models running in parallel, ownership unclear at the seams, and the internal team still developing the muscle to close the gaps. We brought an outside read, collapsed the parallel structures, aligned the teams on a single operating cadence, and rebuilt the governance. The integration started moving again.
TRANSFORMATION & DATA GOVERNANCE
A $5B oncology portfolio running on fragmented data no one trusted.
The field was making decisions from numbers they didn't believe in and everyone knew it. We replaced the architecture with a single source of truth, cut data errors by 90%, and gave the field something they could actually perform to.
HemOnc Commercial Operations Transformation
THERAPEUTIC AREA EXPERTISE
We know the market.
We know the pressure.
Our team has built commercial infrastructure across the therapeutic areas where the regulatory complexity, payer skepticism, and patient access challenges are highest.
Endocrinology
-
GLP-1 payer budget pressure
-
Employer coverage restrictions
-
CMS access with prior auth strings
Oncology / HemOnc
-
IRA price negotiations
-
Buy-and-bill complexity
-
PBM formulary consolidation
CNS / Neurology
-
Long diagnosis timelines
-
Concentrated specialist markets
-
Payer skepticism of early data
Digital Therapeutics
-
No payer reimbursement framework
-
No prescribing workflow
-
Category built from scratch
Dermatology
-
Step therapy and prior auth
-
Hub and co-pay infrastructure
-
Pull-through over access
Immunology
-
Biosimilar erosion
-
Payer-written access playbooks
-
Pre-launch evidence requirements
